• Selective IMPDH2 Inhibition by Berberrubine in Colorectal Ca

  2026-05-27

  The referenced study identifies berberrubine as a novel and selective inhibitor of IMPDH2, a key enzyme implicated in colorectal cancer (CRC) proliferation and poor patient prognosis. Through both in vitro and in vivo experiments, the research demonstrates that berberrubine impairs CRC growth via selective enzymatic targeting, highlighting its potential as an anti-colorectal cancer agent.

• PKM2 Inhibitor (Compound 3k): Selective Disruption of Tumor

  2026-05-27

  PKM2 inhibitor (compound 3k) is a potent, selective small molecule targeting pyruvate kinase M2, disrupting aerobic glycolysis in tumor cells and modulating macrophage polarization. It demonstrates nanomolar antiproliferative activity in key cancer cell lines and shows high selectivity over normal cells. Recent evidence confirms its efficacy in both oncology and immunometabolism models.

• Applied Use of PPT (Propyl Pyrazole Triol) in ERα Signaling

  2026-05-26

  PPT (Propyl Pyrazole Triol) redefines estrogen receptor alpha (ERα) research with unmatched selectivity and proven workflow consistency. Discover how this compound advances assays from gene expression to in vivo modeling, with practical troubleshooting and actionable protocol enhancements.

• Eliminating Pollen Interference in Bioaerosol Spectral Analy

  2026-05-26

  The reference study introduces an advanced approach to remove pollen-induced spectral interference in excitation–emission matrix (EEM) fluorescence spectroscopy, significantly improving hazardous bioaerosol classification accuracy. This innovation holds practical importance for research in environmental biosurveillance and rapid detection of pathogenic substances.

• JNJ-10198409: Precision Platelet-Derived Growth Factor Recep

  2026-05-25

  JNJ-10198409 stands out as a best-in-class platelet-derived growth factor receptor inhibitor, enabling researchers to dissect PDGF-driven biology in oncology, fibrosis, and angiogenesis with unprecedented specificity and reproducibility. Streamlined protocols, robust nanomolar potency, and actionable troubleshooting guidance make it a cornerstone for translational research.

• Pomalidomide (CC-4047): Protocol Enhancements in Myeloma Res

  2026-05-25

  Pomalidomide (CC-4047) from APExBIO empowers researchers to dissect tumor microenvironment dynamics and overcome resistance in multiple myeloma models. This guide translates the latest mutational insights and experimental best practices into actionable protocols, troubleshooting strategies, and comparative advantages for hematological malignancy research.

• PPT (Propyl Pyrazole Triol): Decoding ERα-Driven Gene Networ

  2026-05-24

  Explore how PPT (Propyl Pyrazole Triol), a potent ERα agonist, enables precision dissection of estrogen receptor signaling and ceRNA networks in cancer research. This article unveils advanced mechanistic insights and assay design strategies for next-generation molecular studies.

• BMX Kinase Regulates Lysosomal Acidification in M. tuberculo

  2026-05-23

  This study reveals that Mycobacterium tuberculosis enhances its intracellular survival by hijacking host BMX kinase to phosphorylate ATP6V1E1, thereby inhibiting lysosomal acidification. These findings illuminate a novel pathway for host-pathogen interaction and identify BMX kinase as a promising therapeutic target for tuberculosis intervention.

• LGK-974: A Precision PORCN Inhibitor for Wnt Pathway Researc

  2026-05-22

  LGK-974 stands out as a gold-standard PORCN inhibitor, enabling precise disruption of Wnt signaling for translational cancer research. Its nanomolar potency and unique selectivity empower robust modeling of Wnt-driven tumor regression and combinatorial therapy strategies.

• Aminopeptidase Inhibition Modulates Angiotensin Neural Signa

  2026-05-22

  This study demonstrates that bestatin and amastatin, two aminopeptidase inhibitors, distinctly alter angiotensin-II and angiotensin-III-evoked neuronal responses in the rat brain. The findings clarify a critical enzymatic step in neuropeptide signaling, with implications for mechanistic research into brain angiotensin systems and related pathophysiology.

• Troglitazone: PPARγ Agonist Workflows for Metabolic & Tumor

  2026-05-21

  Troglitazone from APExBIO bridges metabolic research and tumor immunology by enabling precise PPARγ/α pathway activation. This guide details experimental strategies, practical troubleshooting, and new innovations for harnessing Troglitazone’s dual-action in type 2 diabetes and tumor-associated macrophage studies.

• Talin1–Piezo1–YAP Axis Regulates Endothelial Inflammation in

  2026-05-21

  This study reveals that Talin1 acts as a crucial mediator in the Piezo1–YAP signaling axis, orchestrating endothelial cell inflammation central to atherosclerosis. By delineating calcium influx–dependent mechanisms, it offers new insights for targeted anti-inflammatory interventions and highlights the importance of precise calcium modulation in vascular disease research.

• Phosbind Acrylamide: Advanced Phosphate-Binding for SDS-PAGE

  2026-05-20

  Phosbind Acrylamide is a phosphate-binding reagent enabling antibody-free, high-resolution SDS-PAGE detection of protein phosphorylation states. This reagent, supplied by APExBIO, operates at physiological pH and supports robust protein phosphorylation analysis within the 30–130 kDa range.

• Pazopanib (GW-786034): Advanced Workflows for Cancer Researc

  2026-05-20

  Harness the full translational power of Pazopanib (GW-786034), a multi-targeted RTK inhibitor, to dissect angiogenesis and tumor suppression in complex cancer models. This guide details experimental strategies, protocol enhancements, and troubleshooting grounded in recent literature—including the pivotal role of ATRX status in glioma assays.

• Pazopanib (GW-786034): Precision Angiogenesis Inhibition in

  2026-05-19

  Pazopanib (GW-786034) empowers translational cancer research with robust, multi-targeted angiogenesis inhibition and proven synergy in genetically defined models. This article delivers protocol-driven insights, troubleshooting strategies, and comparative value for advanced oncology workflows.

16294 records 1/1087 page Next 12345 下5页 Last page